ergosta-7,9(11),22E-trien-3β-ol | 59202-60-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: ergosta-7,9(11),22E-trien-3β-ol
• 英文别名: (3β,22E)-ergosta-7,9(11),22-trien-3-ol；(22E,24R)-ergosta-7,9,22-trien-3β-ol；ergosta-7,9(11),22-trien-3β-ol；ergosterol D；ergosta-7,9,22-trien-3-β-ol；Antrosterol；(3S,10S,13R,14R,17R)-17-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-10,13-dimethyl-2,3,4,5,6,12,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-ol
• CAS: 59202-60-7
• 化学式: C₂₈H₄₄O
• 分子量: 396.657
• InChiKey: XSMGJKKUFBTARU-SMQIQWERSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.2
• 重原子数：
  29
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.79
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• Derivatives of Ergostatrien-3-Beta-OL From Antrodia Camphorata and Antiglycemic, Antihyperlipidemic and Decreasing Hepatic Fat Use Thereof
  申请人：SHIH Chun-Ching

  公开号：US20170049787A1

  公开（公告）日：2017-02-23

  The present invention provides a method for treating diabetes, hyperlipidemia or hepatic total lipids by using ergostatrien-3β-ol and its derivatives, as well as a method for decreasing blood glucose and HbA1c levels and reducing blood total cholesterol and triglyceride levels, whereas increasing blood HDL-C levels; and a method for decreasing hepatic total lipid and triacylglycerol levels; and increasing expression levels of membrane glucose transporter 4 (GLUT4) and phospho-Akt in skeletal muscle tissue, and phospho-AMPK in both skeletal muscle and liver tissue using ergostatrien-3β-ol and its derivatives.
• US9757393B2
  申请人：——

  公开号：US9757393B2

  公开（公告）日：2017-09-12